Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate

Coulson, Elizabeth; Saravanan, V.; Hamilton, Jennifer D.; Kl, So; Morgan, L.; Heycock, Carol; Rynne, M.; Kelly, Carol

doi:10.1136/ard.2010.144451

Cited by 60 publications

(43 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, a study by Elkayam et al 17 did not demonstrate a detrimental effect of immunosuppressive drugs such as MTX on PPV23 immunogenicity in RA patients. Coulson et al 18 have also suggested that a single PPV23 administration offers up to 10 years of protection against the development of pneumococcal pneumonia in RA patients receiving MTX therapy. Determining serotype-specific IgG concentrations after PPV23 vaccination in patients receiving MTX therapy is recommended 19…”

Section: Discussionmentioning

confidence: 99%

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy

Mori¹,

Ueki

Akeda

et al. 2013

Ann Rheum Dis

View full text Add to dashboard Cite

ObjectivesWe assessed the impact of tocilizumab (TCZ), a humanised monoclonal anti-interleukin-6 receptor antibody, on antibody response following administration of the 23-valent pneumococcal polysaccharide vaccine (PPV23).MethodsA total of 190 patients with rheumatoid arthritis (RA) received PPV23. Patients were classified into TCZ (n=50), TCZ + methotrexate (MTX) (n=54), MTX (n=62) and RA control (n=24) groups. We measured serotype-specific IgG concentrations of pneumococcal serotypes 6B and 23F using ELISA and functional antibody activity using a multiplexed opsonophagocytic killing assay, reported as the opsonisation indices (OIs), before and 4–6 weeks after vaccination. Positive antibody response was defined as a 2-fold or more increase in the IgG concentration or as a ≥10-fold or more increase in the OI.ResultsIgG concentrations and OIs were significantly increased in all treatment groups in response to vaccination. The TCZ group antibody response rates were comparable with those of the RA control group for each serotype. MTX had a negative impact on vaccine efficacy. Multivariate logistic analysis confirmed that TCZ is not associated with an inadequate antibody response to either serotype. No severe adverse effect was observed in any treatment group.ConclusionsTCZ does not impair PPV23 immunogenicity in RA patients, whereas antibody responses may be reduced when TCZ is used as a combination therapy with MTX.

show abstract

Section: Discussionmentioning

confidence: 99%

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy

Mori¹,

Ueki

Akeda

et al. 2013

Ann Rheum Dis

View full text Add to dashboard Cite

show abstract

“…101 Compared with healthy individuals, for patients with RA, similar 61,63,102,103 as well as lower [103][104][105][106] humoral responses to pneumococcal vaccine have been shown, depending on the medication used.…”

Section: Hib and Pneumococcal Vaccinesmentioning

confidence: 97%

Vaccination of patients with autoimmune inflammatory rheumatic diseases

et al. 2014

View full text Add to dashboard Cite

Patients with autoimmune inflammatory rheumatic diseases (AIRDs) are at increased risk of infections. This risk has been further increased by the introduction of biologic agents over the past two decades. One of the most effective strategies to prevent infection is vaccination. However, patients with an AIRD have a compromised immune system, which is further impaired by medication. Another important issue is the possibility of triggering a broad nonspecific response by vaccination, potentially resulting in increased activity of the underlying autoimmune disease. In this Review, we provide an analysis of data on vaccination of patients with an AIRD. Both the efficacy and the safety of vaccination are addressed, together with the epidemiology of vaccine-preventable infectious diseases in different subgroups of adults with AIRDs. Special attention is given to vaccination of patients who are treated with biologic agents.

show abstract

“…было показано, что однократное введение ППВ23 в дебюте ревмато-идного артрита до назначения терапии обеспечивает защиту против пневмококковой пневмонии в течение 10 лет у пациентов с ЮИА на фоне терапии метотрек-сатом [24].…”

Section: актуальностьunclassified

Pneumococcal Vaccination of Patients with Juvenile Idiopathic Arthritis: Review of International Experience

Солошенко¹,

Алексеева²,

Бзарова³

et al. 2017

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate

Abstract: This study suggests that a single administration of pneumovax early in RA offers up to 10 years protection against the development of pneumococcal pneumonia in RA patients on methotrexate.

Cited by 60 publications

References 24 publications

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy

Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy

Vaccination of patients with autoimmune inflammatory rheumatic diseases

Pneumococcal Vaccination of Patients with Juvenile Idiopathic Arthritis: Review of International Experience

Contact Info

Product

Resources

About